Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Recruiting
Observational Study
Endocan
Copeptin
Serum
Preterm Neonates
Respiratory Distress Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 28 Weeks – 36 Weeks
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- Tanta University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Prematurity.
* Gestational age between 28 and 36 weeks.
* Suffering from respiratory distress syndrome.
Exclusion Criteria:
* Intrauterine growth restriction (IUGR).
* Hypoxic ischemic encephalopathy.
* Multiple congenital anomalies.
* Chromosomal abnormalities.
* Preterm le…
Contacts